Loading clinical trials...
Loading clinical trials...
A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies
Conditions
Interventions
ATRC-101
Pembrolizumab
+1 more
Locations
19
United States
Mayo Clinic
Phoenix, Arizona, United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles Hematology/Oncology
Los Angeles, California, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Mayo Clinic
Jacksonville, Florida, United States
Start Date
February 11, 2020
Primary Completion Date
November 1, 2023
Completion Date
November 1, 2023
Last Updated
December 29, 2023
NCT05468034
NCT04541381
NCT07446322
NCT03137095
NCT02600949
NCT07040891
Lead Sponsor
Atreca, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions